SecBot SecBot
SECBOTREPLAY Home › Report › ARGX

ARGX · Argenx announced positive topline results from the Phase 3 ALKIVIA…

ARGENX SE · 6-K filed Aug 17, 2026 at 08:54 ET

At the news

BULLISHIMPACT 8/10

6-K filed Aug 17, 2026 at 08:54 ET

Argenx announced positive topline results from the Phase 3 ALKIVIA trial of VYVGART Hytrulo (efgartigimod) in autoimmune myositis. The study met its primary endpoint (p=0.0011) in the combined IMNM and DM population, showing a 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo. This is the first Phase 3 study to show statistically significant results in IMNM, a subtype with no approved therapy, and represents a major pipeline expansion into rheumatology for argenx, opening a new addressable market of approximately 60,000 patients in the US alone.

  • Phase 3 ALKIVIA trial met primary endpoint (p=0.0011) in combined IMNM and DM population
  • 15.4-point greater improvement in mean TIS at Week 52 vs placebo (47.95 vs 32.56)
  • First Phase 3 study to show statistically significant improvement in IMNM, a subtype with no approved therapy
  • Consistent treatment effect across both IMNM (p=0.0048) and DM (p=0.1093) subtypes

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access